Free Trial

Kalpit Patel Analyst Performance

Analyst at B. Riley

Kalpit Patel is a stock analyst at B. Riley, covering 7 publicly traded companies across a range of sectors. Over the past year, Kalpit Patel has issued 7 stock ratings, including buy and hold recommendations. While full access to Kalpit Patel's proprietary MarketBeat Analyst Rating is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Kalpit Patel's coverage history, rating activity, and performance tendencies — helping individual investors make more informed trading decisions.

Analyst Ratings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
8 Last 3 Years
Buy Recommendations
62.50% 5 Buy Ratings
Companies Covered
7 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy62.5%5 ratings
Hold37.5%3 ratings
Sell0.0%0 ratings

Out of 8 total stock ratings issued by Kalpit Patel at B. Riley, the majority (62.5%) have been Buy recommendations, followed by 37.5% Hold.

Best & Worst Calls

This analyst does not have any ratings with enough history to determine best and worst calls.

Exchange Coverage

ExchangePercentageCount
NASDAQ
100.0% of companies on NASDAQ
7 companies

Kalpit Patel, an analyst at B. Riley, currently covers 7 companies listed on , with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Medical
7 companies
100.0%

Kalpit Patel of B. Riley specializes in stock coverage within the Medical sector.

Coverage Industries

IndustryPercentage
MED - BIOMED/GENE
6 companies
85.7%
MED - DRUGS
1 company
14.3%

Kalpit Patel's Ratings History at B. Riley

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Kymera Therapeutics, Inc. stock logo
KYMR
Kymera Therapeutics
6/3/2025Upgrade$43.13$60.00Buy
Bicycle Therapeutics PLC Sponsored ADR stock logo
BCYC
Bicycle Therapeutics
5/2/2025Lower Price Target$9.19$14.00Neutral
ArriVent BioPharma, Inc. stock logo
AVBP
ArriVent BioPharma
3/20/2025Initiated Coverage$19.60$37.00Buy
Rigel Pharmaceuticals, Inc. stock logo
RIGL
Rigel Pharmaceuticals
3/5/2025Boost Price Target$19.49$24.00Neutral
Geron Corporation stock logo
GERN
Geron
2/18/2025Lower Price Target$2.63$3.50Buy
Verastem, Inc. stock logo
VSTM
Verastem
1/31/2025Boost Price Target$6.39$9.00Buy
Foghorn Therapeutics Inc. stock logo
FHTX
Foghorn Therapeutics
1/30/2025Initiated Coverage$3.98$10.00Buy